Business, energy, technology, markets and global industry news from Business News Today

Seaport Therapeutics

PharmaDeviceNews Seaport Therapeutics
Pharma & Biotech

Seaport Therapeutics’ Glyph platform faces its real test as GlyphAllo advances in depression

Seaport Therapeutics’ GlyphAllo data sharpen the case for oral neuroactive steroids in depression. Read what this could change next.

Read More
Why ARPA-H funding for Seaport Therapeutics could accelerate a new class of lymphatic-targeted medicines
Pharma & Biotech

What Seaport Therapeutics’ Glyph platform reveals about the emerging science of gut lymphatic targeting

ARPA-H backs Seaport Therapeutics’ GlyphCele program targeting gut lymphatics in metabolic disease and pancreatic cancer. Read the analysis.

Read More